Search clinical trials for: minimal residual disease in AML patients

Total 481531 results

Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Minimal Residual Disease | AML, Adult
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Hematologic and Lymphocytic Disorder | Acute Myeloid Leukemia in Remission | FLT3 Gene Mutation | Minimal Residual Disease Persistence

United States
Niguarda Hospital

Recruiting

Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia (AML FLT3)

Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Italy
University of Leipzig
Millennium Pharmaceuticals, Inc.

Completed

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Myelodysplastic Syndromes | Minimal Residual Disease | Acute Myeloid Leukemia in Remission

Germany
Novartis Pharmaceuticals

Completed

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States, Spain, Belgium, Germany, Japan, Taiwan, Turkey, Italy, Australia, Austria, Switzerland, Israel, Bulgaria, France, Norway, Brazil, Poland, Portugal, Czechia, Argentina
Mendus
Amsterdam UMC, location VUmc

Active, not recruiting

Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia (ADVANCE-II)

Acute Myeloid Leukemia in Remission

Norway, Netherlands, Sweden, Finland, Germany
Therapeutic Advances in Childhood Leukemia Consortium
Genzyme, a Sanofi Company

Terminated

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Minimal Residual Disease | Leukemia, Lymphoblastic, Acute | Leukemia, Myelogenous, Acute

United States
Astellas Pharma Global Development, Inc.

Approved for marketing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

United States, Canada, Japan
UNC Lineberger Comprehensive Cancer Center

Completed

Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

Acute Myeloid Leukemia

United States
Chinese PLA General Hospital

Unknown

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

Acute Myeloid Leukemia, in Relapsed or Refractory | Acute Myeloid Leukemia, Elderly, Unfit | Acute Myeloid Leukemia With Positive Minimal Residual Disease

China
Memorial Sloan Kettering Cancer Center
Pfizer

Withdrawn

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | Minimal Residual Disease

United States
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
University of Ulm

Terminated

Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)

Acute Myeloid Leukemia

Germany
University of Bologna

Unknown

Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells

Myeloblastic Leukemia

Italy
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)

Colorectal Cancer | Minimal Residual Disease | Liquid Biopsy | Stage III Colon Cancer
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Colorectal Cancer | Liver Metastases | Minimal Residual Disease | Liquid Biopsy | Stage IV Colorectal Cancer | ctDNA
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Minimal Residual Disease | Liquid Biopsy | ctDNA
Henan Cancer Hospital

Recruiting

The Maintenance Treatment of "ITIVA" in AML Patients

Acute Myeloid Leukemia | Thalidomide | Maintenance Treatment | Minor Residue Disease | Interferon-α-1b | Interleukin-2 | Venentoclax | Azacitidine

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Multiple Myeloma

China
Zhejiang University

Recruiting

Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

Acute Lymphoblastic Leukemia

China
FengYan Jin

Not yet recruiting

A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment (MRD)

Multiple Myeloma | Minimal Residual Disease
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
Guangdong Provincial People's Hospital
Shenzhen Chipscreen Biosciences Co.Ltd

Recruiting

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Minimal Residual Disease | AML, Adult

China
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Not yet recruiting

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Minimal Residual Disease | AML, Adult

China
Assistance Publique - Hôpitaux de Paris
CARPEM, Institut du Cancer Paris; Centre de recherche des Cordeliers; METHYS DX

Recruiting

Circulating Tumor DNA Study in Patients With Endometrial Cancer (ctDNA-endo)

Endometrial Cancer

France
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Mini-invasive Detection of Residual Disease in Breast Cancer Patients in Remission After Primary Chemotherapy

Breast Cancer

Italy
Technische Universität Dresden
AbbVie; University Hospital Heidelberg

Not yet recruiting

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML (VINCENT)

Acute Myeloid Leukemia

Germany
Peking University People's Hospital

Recruiting

Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence

Gastrointestinal Stromal Tumors

China
Xiaojun Xu

Not yet recruiting

Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

Acute Lymphoblastic Leukemia, Pediatric
Masonic Cancer Center, University of Minnesota

Recruiting

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Acute Leukemia | Neurofibromatosis 1 | Hematologic Malignancy | Myelodysplasia | Minimal Residual Disease | Chromosome Abnormality | Monosomy 7 | Remission | Somatic Mutation | Cytogenetic Abnormality | TP53 | Fetal Hemoglobin | Intrachromosomal Amplification of Chromosome... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

Lymphoma

United States
Sun Yat-sen University

Recruiting

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT (SURPASS)

Limited Stage Small Cell Lung Cancer

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Minimal Residual Disease

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Acute Lymphocytic Leukemia
Pfizer

Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

Multiple Myeloma

Japan, Belgium, United States, Netherlands, Australia, Austria, Taiwan, China, Spain, Canada, Korea, Republic of, Israel, Germany, Italy, Czechia, Norway, Finland, France, Sweden, Brazil, Greece, Turkey, United Kingdom, Hungary, Poland, I...
Federico II University

Recruiting

Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients

Hodgkin Lymphoma

Italy
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE)

Acute Myeloid Leukemia in Remission

United States
Fang Wu
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Sun Yat-sen... and other collaborators

Recruiting

ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC (CR1STAL)

Advanced Lung Non-Small Cell Carcinoma

China
Goethe University
University Hospital Schleswig-Holstein

Recruiting

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

ALL, Recurrent, Adult

Germany
M.D. Anderson Cancer Center

Recruiting

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Myeloma Multiple

United States
M.D. Anderson Cancer Center

Recruiting

DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease

Colorectal Cancer | Colon Cancer

United States
Roswell Park Cancer Institute
GlaxoSmithKline

Recruiting

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Plasma Cell Myeloma

United States
First Affiliated Hospital of Zhejiang University
Xiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaborators

Recruiting

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Hematologic Malignancy | Stem Cell Transplant Complications

China
Paolo Ghia

Recruiting

Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) (VALUABLE)

Chronic Lymphocytic Leukemia (CLL)

Italy
M.D. Anderson Cancer Center

Recruiting

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Colorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditions

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) (HTLP-ONCO)

Hematologic Malignancy

France
University Hospital, Lille
Saint-Louis Hospital, Paris, France; Canceropôle Nord Ouest

Recruiting

Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia (FERTILAM)

Acute Myeloid Leukemia

France
Novartis Pharmaceuticals

Recruiting

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Acute Myeloid Leukemia

Spain, Germany, Italy, France
Celularity Incorporated

Recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Hematologic Neoplasms | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Antimetabolites, Antineoplastic | Leukemia in Remission | Relapsed... and other conditions

United States

Search clinical trials for: minimal residual disease in AML patients

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations